BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chu HH, Kim JH, Shim JH, Yoon SM, Kim PH, Alrashidi I. Chemoembolization Plus Radiotherapy Versus Chemoembolization Plus Sorafenib for the Treatment of Hepatocellular Carcinoma Invading the Portal Vein: A Propensity Score Matching Analysis. Cancers (Basel) 2020;12:E1116. [PMID: 32365655 DOI: 10.3390/cancers12051116] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Sun T, Chen L, Kan X, Ren Y, Cao Y, Zhang W, Lu H, Zheng C. A Comparative Analysis of Efficacy of Apatinib Combined with Transarterial Chemoembolization and Transarterial Chemoembolization Alone in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Oncol 2022;2022:1255133. [PMID: 35356254 DOI: 10.1155/2022/1255133] [Reference Citation Analysis]
2 Tao ZW, Cheng BQ, Zhou T, Gao YJ. Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00229-0. [PMID: 34955380 DOI: 10.1016/j.hbpd.2021.12.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chen L, Sun T, Wu L, Zhang W, Ren Y, Xiang D, Liang B, Zheng C. The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma. J Oncol 2021;2021:8169012. [PMID: 34840572 DOI: 10.1155/2021/8169012] [Reference Citation Analysis]
4 Yang Z, Sun JQ, Wang S, Zhuang L, Zheng SS. Response to pretransplant downstaging therapy predicts patient outcome after liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00199-5. [PMID: 34696977 DOI: 10.1016/j.hbpd.2021.09.012] [Reference Citation Analysis]
5 Luo F, Li M, Ding J, Zheng S. The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. Front Oncol 2021;11:635731. [PMID: 34631513 DOI: 10.3389/fonc.2021.635731] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kim GH, Choi SL, Kim JH, Shim JH, Alali M, Kim N. Sorafenib Combined with Chemoembolization for Locally Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion: A Propensity Score Analysis. Life (Basel) 2021;11:1066. [PMID: 34685437 DOI: 10.3390/life11101066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kim GH, Kim JH, Kim PH, Chu HH, Gwon DI, Ko HK. Emerging Trends in the Treatment of Advanced Hepatocellular Carcinoma: A Radiological Perspective. Korean J Radiol 2021;22:1822-33. [PMID: 34431250 DOI: 10.3348/kjr.2021.0229] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ding X, Sun W, Li W, Shen Y, Guo X, Teng Y, Liu X, Zheng L, Li W, Chen J. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study. Cancer 2021. [PMID: 34237154 DOI: 10.1002/cncr.33677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
9 Tan Z, Lu J, Zhu G, Chen L, Wang Y, Zhang Q, Pan T, Wang J, Guo J, Teng G. Portal Vein Irradiation Stent Plus Chemoembolization versus External Radiotherapy Plus Chemoembolization in Hepatocellular Carcinoma with Portal Vein Tumour Thrombus: A Retrospective Study. Cardiovasc Intervent Radiol 2021;44:1414-22. [PMID: 34131776 DOI: 10.1007/s00270-021-02889-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Qiu Z, Shen L, Jiang Y, Qiu J, Xu Z, Shi M, Yu Z, Ma Y, He W, Zheng Y, Li B, Wang G, Yuan Y. Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study. Ann Transl Med 2021;9:283. [PMID: 33708910 DOI: 10.21037/atm-20-5360] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
11 Tang Y, Wang L, Teng F, Zhang T, Zhao Y, Chen Z. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis. Int J Med Sci 2021;18:187-98. [PMID: 33390787 DOI: 10.7150/ijms.50883] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
12 Chu HH, Chun SY, Kim JH, Kim PH, Il Gwon D, Ko HK, Kim N. A prediction model for overall survival after transarterial chemoembolization for hepatocellular carcinoma invading the hepatic vein or inferior vena cava. Eur Radiol 2021;31:4232-42. [PMID: 33241523 DOI: 10.1007/s00330-020-07536-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ohkoshi-Yamada M, Kamimura K, Shibata O, Morita S, Kaidu M, Nakano T, Maruyama K, Ota A, Saito H, Yamana N, Oshikane T, Goto Y, Yoshimura N, Tanabe S, Nakano H, Sakai M, Tanaka Y, Koseki Y, Arao Y, Abe H, Setsu T, Sakamaki A, Yokoo T, Kamimura H, Aoyama H, Terai S. Efficacy and Safety of the Radiotherapy for Liver Cancer: Assessment of Local Controllability and its Role in Multidisciplinary Therapy. Cancers (Basel) 2020;12:E2955. [PMID: 33066141 DOI: 10.3390/cancers12102955] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]